ASLAN PHARMACEU/ADR (NASDAQ:ASLN)’s stock price traded up 36.1% during trading on Monday . The company traded as high as $8.18 and last traded at $5.20, 15,433,472 shares changed hands during trading. An increase of 5,303% from the average session volume of 285,622 shares. The stock had previously closed at $3.82.

ASLN has been the subject of several research analyst reports. BTIG Research lowered ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a research report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of ASLAN PHARMACEU/ADR in a report on Monday, November 25th. Zacks Investment Research raised ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 target price on the stock in a research note on Monday, November 4th. Finally, Piper Jaffray Companies raised ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 target price on the stock in a research note on Monday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $4.00.

The company has a debt-to-equity ratio of 1.12, a current ratio of 1.88 and a quick ratio of 3.80. The firm has a market cap of $87.50 million, a PE ratio of -1.95 and a beta of 3.31. The company’s 50 day moving average price is $1.70 and its 200 day moving average price is $2.47.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last announced its earnings results on Thursday, October 31st. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.19. Sell-side analysts expect that ASLAN PHARMACEU/ADR will post -0.69 earnings per share for the current fiscal year.

An institutional investor recently raised its position in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC lifted its stake in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,100 shares of the company’s stock after acquiring an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.12% of the company’s stock.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

Further Reading: What does a market perform rating mean?

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.